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background:  Both clopidogrel (C) and Ticagrelor (T) are P2Y12 ADP receptor antagonists. In a phase III clinical trial (PLATO) T showed reduction in 
the rate of the primary composite endpoint myocardial infarction, stroke or cardiovascular death over C in patients with acute coronary syndromes. 
T, in addition to P2Y12 inhibition, inhibits cell uptake of adenosine and thus, may augment adenosine effects. Adenosine protects the heart against 
ischemia-reperfusion injury. We compared the effects of C and T on myocardial infarct size (IS). 
methods:  Rats received oral T (0, 75, 150 or 300 mg/kg/d) or C (30 or 90 mg/kg/d) for 7d and were subjected to 30 min coronary artery ligation 
and 24h reperfusion. Area at risk (AR) was assessed by blue dye and IS by TTC staining. 
results: There were 8 animals per group. Body weight, left ventricular weight and the size of the AR were comparable between groups. IS was 
53.1±2.4% of the LV in the control group. T, dose-dependently, reduced IS [42.2±1.6% (p=0.001), 34.7±1.3% (p<0.001), and 22.3±1.3% 
(p<0.001), respectively]. In contrast, C had no effect (50.2±1.1% and 50.5±2.0%, respectively). Platelet inhibition was comparable between the T 
150mg/kg/d and the C 30mg/kg/d and between the T 300mg/kg/d and C 90mg/kg/d. T increased tissue adenosine levels and cyclooxygenase-2 
activity. The IS-limiting effect of T 300mg/kg/d (16.8±1.7% of the LV) was reversed with CGS, an adenosine receptor blocker (42.3±3.1%; p=0.001 
vs. T alone; p=0.074 vs. control) and was partially inhibited with aspirin 10 mg/kg/d (21.1±2.6%; p=0.57) and 25 mg/kg/d (31.1±1.9%; p<0.001), 
but not with 5 mg/kg/d (14.7±1.0%). 
Conclusions: T, but not C protects against ischemia-reperfusion injury and reduces myocardial IS. The protective effect is related to the inhibition 
of adenosine uptake and is attenuated by high doses of aspirin. This additional adenosine-mediated “pleiotropic” effect of T may (partially) explain 
the superiority of T over C in the clinical setting.
